索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病中的临床应用研究
目的分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病（AML）患者挽救性治疗策略在异基因造血干细胞移植（allo-HSCT）前后应用的效果。方法16例难治复发性FLT3突变阳性AML患者（10例为移植前难治复发，6例为移植后复发）纳入回顾性研究；索拉非尼应用方法包括索拉非尼联合化疗诱导缓解和缓解后索拉非尼单药维持治疗。结果16例患者中13例经1～2个疗程诱导缓解治疗获完全缓解（CR），包括7例移植前难治复发和6例移植后复发患者。移植后中位随访472（59～1 569）d，12例存活，4例死亡，死亡原因包括复发3例、急性移植物抗宿主病1例。16例患者移植后2年累积总生存率和无病生存率分别...
Saved in:
| Published in | 中华血液学杂志 Vol. 37; no. 4; pp. 292 - 296 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
南方医科大学南方医院血液科, 广州,510515
2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-2727 |
| DOI | 10.3760/cma.j.issn.0253-2727.2016.04.009 |
Cover
| Abstract | 目的分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病（AML）患者挽救性治疗策略在异基因造血干细胞移植（allo-HSCT）前后应用的效果。方法16例难治复发性FLT3突变阳性AML患者（10例为移植前难治复发，6例为移植后复发）纳入回顾性研究；索拉非尼应用方法包括索拉非尼联合化疗诱导缓解和缓解后索拉非尼单药维持治疗。结果16例患者中13例经1～2个疗程诱导缓解治疗获完全缓解（CR），包括7例移植前难治复发和6例移植后复发患者。移植后中位随访472（59～1 569）d，12例存活，4例死亡，死亡原因包括复发3例、急性移植物抗宿主病1例。16例患者移植后2年累积总生存率和无病生存率分别为（75.0±10.8）%和（50.5±13.7）%。索拉非尼主要不良反应为皮疹，移植前应用者皮疹发生率低于移植后应用者（30.0%对75.0%, P=0.043）。结论索拉非尼作为难治复发性FLT3突变阳性AML挽救性治疗策略，移植前后应用均能降低移植后患者的复发率，提高生存率。 |
|---|---|
| AbstractList | 目的分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病（AML）患者挽救性治疗策略在异基因造血干细胞移植（allo-HSCT）前后应用的效果。方法16例难治复发性FLT3突变阳性AML患者（10例为移植前难治复发，6例为移植后复发）纳入回顾性研究；索拉非尼应用方法包括索拉非尼联合化疗诱导缓解和缓解后索拉非尼单药维持治疗。结果16例患者中13例经1～2个疗程诱导缓解治疗获完全缓解（CR），包括7例移植前难治复发和6例移植后复发患者。移植后中位随访472（59～1 569）d，12例存活，4例死亡，死亡原因包括复发3例、急性移植物抗宿主病1例。16例患者移植后2年累积总生存率和无病生存率分别为（75.0±10.8）%和（50.5±13.7）%。索拉非尼主要不良反应为皮疹，移植前应用者皮疹发生率低于移植后应用者（30.0%对75.0%, P=0.043）。结论索拉非尼作为难治复发性FLT3突变阳性AML挽救性治疗策略，移植前后应用均能降低移植后患者的复发率，提高生存率。 目的 分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病(AML)患者挽救性治疗策略在异基因造血干细胞移植(allo-HSCT)前后应用的效果.方法 16例难治复发性FLT3突变阳性AML患者(10例为移植前难治复发,6例为移植后复发)纳入回顾性研究;索拉非尼应用方法包括索拉非尼联合化疗诱导缓解和缓解后索拉非尼单药维持治疗.结果 16例患者中13例经1～2个疗程诱导缓解治疗获完全缓解(CR),包括7例移植前难治复发和6例移植后复发患者.移植后中位随访472(59～1 569)d,12例存活,4例死亡,死亡原因包括复发3例、急性移植物抗宿主病1例.16例患者移植后2年累积总生存率和无病生存率分别为(75.0±10.8)％和(50.5±13.7)％.索拉非尼主要不良反应为皮疹,移植前应用者皮疹发生率低于移植后应用者(30.0％对75.0％,P=0.043).结论 索拉非尼作为难治复发性FLT3突变阳性AML挽救性治疗策略,移植前后应用均能降低移植后患者的复发率,提高生存率. |
| Abstract_FL | Objective To analyze the effect of sorafenib as salvage therapy used before and/or after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in refractory relapsed FLT3-positive acute myeloid leukemia (AML).Methods A total of 16 patients with refractory relapsed FLT3-positive AML,including 10 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT,were enrolled in this retrospective study.Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission,and sorafenib monotherapy as mauntenance treatment after complete remission (CR).Results Thirteen of the 16 patients achieved CR after one or two courses of induction therapy,including 7 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT.With a median follow up of 472 (range,59-1 569) days post-transplantation,12 patients survived and 4 died.Causes of death included leukemia relapse (n=3) and acute graft-versus-host disease (n=l).The 2-year overall and disease-free survival post-transplantation of the 16 patients were (75.0± 10.8)％ and (50.5± 13.7)％ respectively.The main side effect of sorafenib was the skin rash.The incidence of rash was lower in the patients used sorafenib pre-transplantation than those post-transplantation (30.0％ vs 75.0％,P=0.043).Conclusion Sorafenib used as salvage therapy befor and/or after transplantation for refractory relapsed FLT3-positive AML could reduce the relapse rate and improve the survival. |
| Author | 张钰 宣丽 范志平 黄芬 江千里 许娜 高雅 孙竞 刘启发 |
| AuthorAffiliation | 南方医科大学南方医院血液科,广州510515 |
| AuthorAffiliation_xml | – name: 南方医科大学南方医院血液科, 广州,510515 |
| Author_xml | – sequence: 1 fullname: 张钰 宣丽 范志平 黄芬 江千里 许娜 高雅 孙竞 刘启发 |
| BookMark | eNo9kE1LAlEUhu_CILX-RItoM9OduXfuzCxDsgKhRe7lOs74QY7mEGkrg1r0hUSWJhYVRVYEkRKi2a-Zmdv8i0aMNucc3vNwXs4bAgGzYOoALAiQRzKBi1qe8jk-a1kmD0UJcaIsyrwIBcJDzEOoBkDwX58GIcvKQYj9PQ6CIuvdu8eH3vWN8_5lj9p2f-CejNyLM7f65H4M2WXDaXe81rc_Ow-nTm2sR2NxxF72nFrTa3bHXPXRr97rOesO2dXo567KGgd2_4219u1-zxkcOYM6q3fYbZ09f86AKYNuWvrsXw-DjehyPLLKxdZX1iJLMU6TFJVLQoEKskYMrFOsalA1VEQp1rCOIBIkKoiKQaBGVP8RSSEYJ42UmBLEFCFUlQgKg_nJ1R1qGtRMJ3KF7ZLp-yV2M-VKeZwNxH4yPjg3AbVMwUxvZX20WMrmaamSIETBiohkCf0CVJuSBA |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.issn.0253-2727.2016.04.009 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation |
| DocumentTitle_FL | Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation |
| EndPage | 296 |
| ExternalDocumentID | zhxyx201604009 668482375 |
| GrantInformation_xml | – fundername: 国家自然科学基金重点项目; 国家自然科学基金; 国家自然科学基金青年基金; 广东省自然科学基金(2014A030310171) Key Project of National Natural Science Foundation; National Natural Science Foundation; National Natural Science Foundation of China Youth Fund; Natural Science Foundation of Guangdong Province funderid: (U1401221); (81270647); (81300445); (U1401221); (81270647); (81300445); (2014A030310171) |
| GroupedDBID | --- -05 2B. 2C~ 2RA 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 F5P OK1 RPM TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX |
| ID | FETCH-LOGICAL-c589-b01a17c6f4ea49c09f93aa4c4e30315a128f60c6900458644bfd2d12d66a9563 |
| ISSN | 0253-2727 |
| IngestDate | Thu May 29 04:03:11 EDT 2025 Wed Feb 14 10:20:12 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 4 |
| Keywords | 索拉非尼 基因,FLT3 Gene,FMS-like tyrosine kinase 3 Sorafenib Leukemia,myeloid,acute 白血病,髓样,急性 造血干细胞移植 Hematopoietic stem cell transplantation |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c589-b01a17c6f4ea49c09f93aa4c4e30315a128f60c6900458644bfd2d12d66a9563 |
| Notes | Objective To analyze the effect of sorafenib as salvage therapy used before and/or after allogeneic hematopoietic stem cell transplantation （allo-HSCT） in refractory relapsed FLT3-positive acute myeloid leukemia （AML）. Methods A total of 16 patients with refractory relapsed FLT3-positive AML, including 10 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT, were enrolled in this retrospective study. Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission, and sorafenib monotherapy as mauntenance treatment after complete remission （CR）. Results Thirteen of the 16 patients achieved CR after one or two courses of induction therapy, including 7 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT. With a median follow up of 472 （range, 59-1 569） days post-transplantation, 12 patients survived and 4 died. Causes of death included leukemia relapse （n=3） and acute graft-versus-host disease （n=1）. The 2-year overall and disease-free sur |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_zhxyx201604009 chongqing_primary_668482375 |
| PublicationCentury | 2000 |
| PublicationDate | 2016 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – year: 2016 text: 2016 |
| PublicationDecade | 2010 |
| PublicationTitle | 中华血液学杂志 |
| PublicationTitleAlternate | Chinese Journal of Hematology |
| PublicationTitle_FL | Chinese Journal of Hematology |
| PublicationYear | 2016 |
| Publisher | 南方医科大学南方医院血液科, 广州,510515 |
| Publisher_xml | – name: 南方医科大学南方医院血液科, 广州,510515 |
| SSID | ssj0042014 ssib051368330 ssib017477332 ssib001103535 ssib058574913 |
| Score | 2.0802176 |
| Snippet | 目的分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病（AML）患者挽救性治疗策略在异基因造血干细胞移植（allo-HSCT）前后应用的效果。方法16例难治复发性FLT3突变阳... 目的 分析索拉非尼作为难治复发性FLT3突变阳性急性髓系白血病(AML)患者挽救性治疗策略在异基因造血干细胞移植(allo-HSCT)前后应用的效果.方法 16例难治复发性FLT3突变阳... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 292 |
| SubjectTerms | 基因，FLT3 白血病，髓样，急性 索拉非尼 造血干细胞移植 |
| Title | 索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病中的临床应用研究 |
| URI | http://lib.cqvip.com/qk/93752X/201604/668482375.html https://d.wanfangdata.com.cn/periodical/zhxyx201604009 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central issn: 0253-2727 databaseCode: RPM dateStart: 20150101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ omitProxy: true ssIdentifier: ssj0042014 providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFA5tBZ8URcVaL31wQFhSc5lJZh4nu1mKqC9W6NuSzW5aBLdVW6h9qqAP3ihitbVUUVGsiiC2SGmt_8S37sb9F54zyaaxiLeHDYeTM-e62fkmOxdNO2lTGnImaroRmlWdmq6jc1at6fifTL0WRYxH-I_uufPO4EV6ZpgNd3V_y81ampyoDoTTv1xX8j9VBR7UFVfJ_kNlM6XAABrqC1eoMFz_qsbEd4lHibSI7xDuES6IL4goEeETnxHPIF6R-JR4wEkITjyphIvIBEIwIkzFMYh0kfAs4nmoWcBdF_VAW8mVZkk8PyfDiAQoWkKCl_N6ymeHbFQhJSDVzu1EBXhg_2QPCZbjCCI9IlRzkExdEcpdTqSJYshxCWdpSLKkOGCLdoKkKn7gyJQQVMlQFQk4ZqQcCZqdPELP6WQYG_dzdiFyFTxGXiLSURkEGcXxIMasV1eMItrBoCFdRkG18om0O06WCqgaSsHtrL0iwCe7gA0heoyJYxyyWFAOmESUO77ZKMQhFUWlCrSDXjTDoWiFTi6TxIMqVkg9h3xi7HDPVyzOlRSUGmpQzuqZfyWUrFVN-wyL2brlJtstdDq4ZFed9EGm-d4qOYYwBT5WcrTwzj4VZ03BgxBeDgYuKSMDmRGcGemonYINsY0nslmejsMp7oXEurVdlgtAcMfLNECeNttG6zA2dt3cbnrMtB2u5j4nwIqCNbUbXMf8bu1U6t_pP3mHO6eMjjVGrgAeVMvzGlHQGMkhyaF92t50CNgvk-d5v9Y1PXpAG49XX7bu3m4_fdb8-GVrc2lrbb11b7P16EFr5k3r00b8eL65tNxe_Ap089X95izy8SmL391ozi60F1ZQbuY1XNvvH8YrG_GTze8vZuL5W1trH-LFm1trq831O831uXhuOX4-F7_9fFC7UPaHioN6ehqKHjIudMhPYLqhE9F6QEVoiEjYQUBDWrfxoJYAcGbkGKEjcJDGYZRTjWpWzbRqjhMI5tiHtJ7GWKN-WOs3KXTapgG5rga0GoQ4MwAQKkCXSIQ1t96r9WW5qowne95Uslr2aifS7FXSX8JrlenRqetTmG1EBOLIb9v3aXtAkuEnmcp5VOuZuDpZPwbYfqJ6XH1DfgBNO8k8 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%B4%A2%E6%8B%89%E9%9D%9E%E5%B0%BC%E4%BD%9C%E4%B8%BA%E6%8C%BD%E6%95%91%E6%80%A7%E6%B2%BB%E7%96%97%E5%9C%A8%E9%9A%BE%E6%B2%BB%E5%A4%8D%E5%8F%91%E6%80%A7FLT3%E7%AA%81%E5%8F%98%E9%98%B3%E6%80%A7%E6%80%A5%E6%80%A7%E9%AB%93%E7%B3%BB%E7%99%BD%E8%A1%80%E7%97%85%E4%B8%AD%E7%9A%84%E4%B8%B4%E5%BA%8A%E5%BA%94%E7%94%A8%E7%A0%94%E7%A9%B6&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E5%BC%A0%E9%92%B0+%E5%AE%A3%E4%B8%BD+%E8%8C%83%E5%BF%97%E5%B9%B3+%E9%BB%84%E8%8A%AC+%E6%B1%9F%E5%8D%83%E9%87%8C+%E8%AE%B8%E5%A8%9C+%E9%AB%98%E9%9B%85+%E5%AD%99%E7%AB%9E+%E5%88%98%E5%90%AF%E5%8F%91&rft.date=2016&rft.issn=0253-2727&rft.volume=37&rft.issue=4&rft.spage=292&rft.epage=296&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-2727.2016.04.009&rft.externalDocID=668482375 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93752X%2F93752X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |